Document is current
Any future updates will be listed below
-
Authors
Saba, James A https://orcid.org/0000-0003-3453-8151
Huang, Zixuan https://orcid.org/0000-0001-6483-6606
Schole, Kate L
Ye, Xianwen
Bhatt, Shrey D
Li, Yi
Timp, Winston
Cheng, Jingdong https://orcid.org/0000-0003-4442-377X
Green, Rachel https://orcid.org/0000-0001-9337-2003
-
Funding
Funding for this research was provided by:
Howard Hughes Medical Institute (HHMI_GREEN)
HHS | NIH | National Cancer Institute (F30CA260910)
HHS | NIH | National Institute of General Medical Sciences (T32GM136577)
National Key R & D Program of China (2023YFC2413204)
National Natural Science Foundation of China (32371350)
Shanghai Municipal Science and Technology Commission (22410712400)
Shanghai Municipal Science and Technology Commission (22ZR1413600)
HHS | NIH | National Human Genome Research Institute (HG010538)
- License Information
-
More Information
Article History
Received: 16 August 2024
Revised: 13 October 2024
Accepted: 16 October 2024
First Online: 12 November 2024
Disclosure and competing interests statement
: RG is a member of the Advisory Editorial Board of The EMBO Journal. This has no bearing on the editorial consideration of this article for publication. RG is on the scientific advisory board of Alltrna, Initial Therapeutics, and Arrakis Pharmaceuticals and serves as a consultant for Vertex Pharmaceuticals, Bristol-Myers Squibb (Celgene), Monta Rosa Therapeutics, and Flagship Pioneering. RG previously served on the scientific advisory board at Moderna. WT has two patents (8,748,091 and 8,394,584) licensed to ONT and received reimbursement for travel, accommodation, and/or conference fees to speak at events organized by ONT.
